GreggEWLiYWangJ, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014;370(16):1514-1523.
2.
BenjaminEJViraniSSCallawayCW, et al. Heart disease and stroke statistics—2018 update: a report from the American Heart Association. Circulation. 2018;137(12):e67-e492.
3.
YancyCWJessupMBozkurtB, et al. 2013 ACCF/AHA guidelines for the management of heart failure: a report of the American College of Cardiology Foundation / American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240-e327.
4.
OhkumaTKomoritaYPetersSAWoodwardM.Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals. Diabetologia. 2019;62(9):1550-1560.
5.
American Diabetes Association. Section 9: pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes – 2020. Diabetes Care. 2020;43(Suppl 1):S98-S110.
6.
ZinmanBWannerCLachinJM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
7.
NealBPerkovicVMahafferyKW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657.
8.
PerkovicVJardineMJNealB, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295-2306.
9.
McMurrayJJVSolomonSDInzucchiSE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995-2008.
10.
WiviottSDRazIBonacaMP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347-357.
